0001209191-22-041994.txt : 20220712
0001209191-22-041994.hdr.sgml : 20220712
20220712211457
ACCESSION NUMBER: 0001209191-22-041994
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220701
FILED AS OF DATE: 20220712
DATE AS OF CHANGE: 20220712
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Grant Papanek Julie
CENTRAL INDEX KEY: 0001673237
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40431
FILM NUMBER: 221080059
MAIL ADDRESS:
STREET 1: 2765 SAND HILL ROAD
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER NAME:
FORMER CONFORMED NAME: Papanek Julie
DATE OF NAME CHANGE: 20160427
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001845337
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832415215
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 395 OYSTER POINT BLVD STE 217
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080-1930
BUSINESS PHONE: 206-913-4300
MAIL ADDRESS:
STREET 1: 395 OYSTER POINT BLVD STE 217
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080-1930
FORMER COMPANY:
FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC
DATE OF NAME CHANGE: 20210209
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2022-07-01
2022-07-06
0
0001845337
Day One Biopharmaceuticals, Inc.
DAWN
0001673237
Grant Papanek Julie
395 OYSTER POINT BLVD, SUITE 217
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2022-07-01
4
S
0
1000
20.00
D
464000
I
See Footnote
Common Stock
2022-07-05
4
S
0
800
20.00
D
463200
I
See Footnote
Common Stock
362
I
See Footnote
Common Stock
9663645
I
See Footnote
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 28, 2021.
Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose.
This amendment to Form 4 is filed to include holdings by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 (the "Revocable Trust"), of which the Reporting Person and her spouse are co-trustees, that were inadvertently omitted from the Form 4 filed on July 6, 2022. These shares were received by the Revocable Trust in one or more prior distributions-in-kind by Canaan XI L.P. for no consideration pursuant to the exemptions afforded by Rules 16a-9 and 16a-13 of the Act. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
/s/ Charles N. York II, Attorney-in-Fact
2022-07-12